Nature Communications (Dec 2022)
Ligand recognition and activation of neuromedin U receptor 2
- Wenli Zhao,
- Wenru Zhang,
- Mu Wang,
- Minmin Lu,
- Shutian Chen,
- Tingting Tang,
- Gisela Schnapp,
- Holger Wagner,
- Albert Brennauer,
- Cuiying Yi,
- Xiaojing Chu,
- Shuo Han,
- Beili Wu,
- Qiang Zhao
Affiliations
- Wenli Zhao
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Wenru Zhang
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine
- Mu Wang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Minmin Lu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Shutian Chen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Tingting Tang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Gisela Schnapp
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry
- Holger Wagner
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry
- Albert Brennauer
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry
- Cuiying Yi
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Xiaojing Chu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Shuo Han
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Beili Wu
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Qiang Zhao
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- DOI
- https://doi.org/10.1038/s41467-022-34814-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 10
Abstract
Neuromedin U receptor 2 is an emerging attractive target for treating obesity. Here, a Cryo-EM structure of NmU-25–NMU2–Gi1 provides the structural basis for the designation of highly selective drugs.
